Neutralizing Tumor Acidity to Improve Cancer Immunotherapy

Episode Summary

Executive Summary: Ryan Beale explains Dive Biosciences’ strategy to treat tumor acidity as a foundational, upstream driver of immune evasion and drug resistance. The company’s transdermal DMAX platform aims to deliver buffering agents systemically, with lead candidate Dive800 entering first-in-human oncology studies after promising gout data and preclinical evidence that raising pH can restore immune function and improve therapy response.

Main Topics: Tumor acidity as an upstream driver of resistance (Priority: 5/5): Beale argues acidic tumor microenvironments suppress T-cell function, promote immune evasion, and weaken checkpoint and other therapies, making acidity a broad leverage point rather than a single-pathway target. Mechanistic evidence for immune suppression in acidic environments (Priority: 5/5): The conversation highlights Dive’s findings that T-cell responses, chemokine-driven migration, and cytokine production are reduced in acidic conditions even when receptors remain intact. DMAX transdermal delivery platform (Priority: 5/5): Dive’s platform is designed to move molecules through the skin into circulation with oral-like bioavailability and needle-like speed, potentially solving adherence and GI limitations seen with oral bicarbonate. Dive800 and the oncology development path (Priority: 5/5): Dive800 is a topically dosed, systemically active buffer intended to raise extracellular tumor pH; initial clinical work will focus on accessible cutaneous/superficial lesions with rich biomarker readouts. Human proof-of-concept from gout program (Priority: 4/5): The company uses its phase two gout study as human validation that its transdermal platform can modulate pH systemically, helping de-risk oncology development. Pipeline breadth beyond cancer (Priority: 3/5): Beale frames DMAX as molecule-agnostic, with additional assets in gout, aesthetics, and possible future inflammatory indications such as atherosclerosis and neurodegenerative disease. Financing, regulatory, and execution risks (Priority: 4/5): The company remains privately funded and sees scientific validation, regulatory acceptance of a novel route/mechanism, and financing as the main hurdles ahead.

Key Arguments: Acidity is a foundational, upstream checkpoint in immuno-oncology because it affects the entire tumor ecology, not just one receptor or pathway. The company’s preclinical work suggests acidic environments directly impair CD8 T-cell function, migration, and cytokine production, while receptor expression can remain preserved. Oral bicarbonate failed clinically largely because patients could not tolerate or adhere to effective dosing; transdermal delivery may bypass GI limitations and achieve meaningful systemic exposure. Dive800 aims to restore physiologic pH in the tumor microenvironment so immune cells can function more effectively and therapies may work better. Human gout data provide proof that the platform can modulate pH in people, supporting translational confidence for oncology. The DMAX platform is molecule-agnostic, so the company views itself as a platform business rather than a single-product company. Initial oncology studies are designed to produce mechanistic readouts, not just efficacy claims, because the key question is whether pH changes can be reproduced in human tumors. Future combination potential is broad, including PD-1 inhibitors, LAG-3 agents, ADCs, bispecifics, and cell therapies that depend on a healthier immune microenvironment.

Data Points: CD8 tumor-reactive response reduction: roughly 6-fold - Observed in acidic versus neutral conditions in the company’s work on T-cell function pH comparison in lab study: pH 6.6 versus pH 4.7 - Used to compare tumor-reactive CD8 responses under different acidity conditions Tumor pH range discussed: 6.4 to 6.8 - Range where the immune system was described as falling asleep in the acidic tumor microenvironment Checkpoint inhibitor nonresponse: roughly 2 in 3 patients - Among patients eligible for checkpoint inhibition, only about one-third respond Checkpoint inhibitor eligibility: more than half of patients with advanced cancer - Described as eligible for checkpoint inhibition in recent work Gout phase 2 sample size: 98 patients - Randomized, double-blind, vehicle-controlled phase two study in acute gout Gout trial sites: 20 U.S. trial sites - Multi-site phase two study supporting platform validation Gout dosing duration: 7 days - Human study duration during which biomarker changes were observed Development timing: before year end this year - Planned start of first-in-human oncology trials Readout timing: end of this year and early next year - Expected initial PK, PD, and biomarker results from oncology studies

Pivotal Quotes: "acidity is a very upstream checkpoint on your immune system" — Ryan Beale: Explaining why tumor acidity is a broad and foundational oncology target "the T cells could still smell the tumor, they just couldn’t walk towards it" — Ryan Beale: Describing functional impairment of immune cell migration in acidic environments "we are restoring physiologic pH in that tumor microenvironment" — Ryan Beale: Summarizing the intended effect of Dive800

Implications: If Dive’s platform translates in humans, acidity could become a new class of upstream oncology target and a combination partner for many therapies. Positive human pH and immune biomarker data would also broaden DMAX beyond cancer into inflammatory disease.